Atuliflapon

• CAT Number: I022879
• CAS Number: 2041075-86-7
• Molecular Formula: C24H26N6O3
• Molecular Weight: 446.50
• Purity: ≥95%
• Synonyms: (1R,2R)-2-[4-(5-methyl-1H-pyrazol-3-yl)benzoyl]-N-(4-oxo-6,7-dihydro-5H-pyrazolo[1,5-a]pyrazin-3-yl)cyclohexane-1-carboxamide
• InChI: InChI=1S/C24H26N6O3/c1-14-12-19(29-28-14)15-6-8-16(9-7-15)22(31)17-4-2-3-5-18(17)23(32)27-20-13-26-30-11-10-25-24(33)21(20)30/h6-9,12-13,17-18H,2-5,10-11H2,1H3,(H,25,33)(H,27,32)(H,28,29)/t17-,18-/m1/s1
• InChIKey: ROTWSDMXHVGAHZ-QZTJIDSGSA-N
• SMILES: CC1=CC(=NN1)C2=CC=C(C=C2)C(=O)C3CCCCC3C(=O)NC4=C5C(=O)NCCN5N=C4

Atuliflapon (Cat No.: I022879) is a potent and selective inhibitor of 5-lipoxygenase-activating protein (FLAP), a critical regulator in the leukotriene biosynthesis pathway. By blocking FLAP, Atuliflapon reduces leukotriene-mediated inflammatory responses, making it a promising compound for studying asthma, chronic obstructive pulmonary disease (COPD), and other inflammatory disorders. Researchers use Atuliflapon to investigate mechanisms of immune modulation, inflammation resolution, and lipid mediator signaling. Its high specificity provides a valuable tool for dissecting leukotriene-driven pathways and exploring potential therapeutic interventions.

Reference

[1]. Daniel Pettersen, et al. Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease. J Med Chem. 2019 May 9;62(9):4312-4324.
[Content Brief]